Astellas Pharma, Inc. v. Sandoz Inc.
Case Number:
23-2032
Court:
Nature of Suit:
835 Patent - (ANDA) (Fed. Qst.)
Companies
- Allergan PLC
- Astellas Pharma Inc.
- Aurobindo Pharma Ltd.
- Lupin Ltd.
- Prinston Pharmaceutical Inc.
- Sandoz International GmbH
- Teva Pharmaceutical Industries Ltd.
- Zydus Pharmaceuticals Inc.
Sectors & Industries:
-
September 18, 2024
Fed. Circ. Revives Astellas Patent Axed As Natural Law
The Federal Circuit on Wednesday vacated a lower court's invalidation of an Astellas Pharma overactive bladder medication patent for claiming only a natural law, saying the holding was improper because the generics makers accused of infringement never made that argument.
-
August 07, 2024
Judge's Pharma Comments Could Decide Ineligibility Appeal
A Federal Circuit panel on Wednesday was willing to explore Astellas Pharma's argument that a Nebraska federal judge should be taken off its infringement case over the bladder medication Myrbetriq, given statements that showed a potential bias against the pharmaceutical industry, but also made clear that such reassignments are rare and difficult.
-
May 09, 2024
Fed. Circ. Lifts Ban On Generic Cos.' Bladder Drugs
The Federal Circuit on Thursday rejected Astellas Pharma's latest effort to stop the launch of generic drugs that would compete with its own blockbuster overactive bladder medication and lifted a temporary ban that was put in place by the appeals court in April.